Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Abbott Laboratories (ABT) - $25 value - yours FREE >>
Novartis AG (NVS) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories (ABT) - $25 value - yours FREE >>
Novartis AG (NVS) - $25 value - yours FREE >>
Image: Bigstock
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Pfizer Inc. (PFE - Free Report) announced positive results from the phase III study, S-TRAC, (Sunitinib Trial in Adjuvant Renal Cancer) on Sutent.
The randomized, double-blind trial evaluated Sutent in comparison to placebo in the adjuvant setting in patients who are at high risk of renal cell carcinoma (RCC). Results showed that the trial met the primary endpoint of improving disease-free survival as determined by a blinded independent central review in RCC patients with a high risk of recurrence after surgery. Adjuvant therapy is expected to lower the risk of recurrence in patients suffering from early-stage cancer.
Pfizer expects to report full efficacy and safety data from the trial at the ESMO 2016 Congress in Oct 2016.
PFIZER INC Price
PFIZER INC Price | PFIZER INC Quote
We note that Sutent is approved for advanced RCC, imatinib-resistant or -intolerant gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumors. As per the information provided by the company, RCC is the most common type of kidney cancer, accounting for around 90% of all kidney cancers. The product’s sales increased 22% operationally (excluding currency impact) year over year in the first quarter of 2016, primarily driven by price increases in the U.S., as well as strong demand in most markets.
The RCC market is already pretty crowded. Note that the FDA had approved Exelixis, Inc.’s (EXEL - Free Report) Cabometyx in Apr 2016 for the treatment of advanced RCC in patients who received prior anti-angiogenic therapy. In Nov 2015, the FDA approved Opdivo for the same indication.
Pfizer currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the healthcare sector include Abbott Laboratories (ABT - Free Report) and Novartis AG (NVS - Free Report) . Both stocks carry the same rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>